The first half of 2025 has seen an acceleration of M&A activity, including large-scale life sciences transactions, such as Merck’s $3.9 billion acquisition of SpringWorks, Sanofi’s $9.5 billion acquisition of Blueprint...more
8/14/2025
/ Acquisitions ,
Antitrust Litigation ,
Antitrust Provisions ,
Enforcement Actions ,
EU ,
European Commission ,
Hatch-Waxman ,
Johnson & Johnson ,
Life Sciences ,
Merger Controls ,
Mergers ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Regulatory Authority ,
Sanofi ,
Settlement Agreements ,
UK ,
UK Competition and Markets Authority (CMA)
The last year (and particularly the last few months) of the Biden Administration brought a flurry of activity from the Federal Trade Commission (FTC) in the life sciences space, continuing a yearslong pattern of close...more
2/21/2025
/ Acquisitions ,
Antitrust Provisions ,
Competition ,
EU ,
European Commission ,
Federal Trade Commission (FTC) ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Pharmacy Benefit Manager (PBM) ,
Popular ,
Sherman Act ,
UK ,
UK Competition and Markets Authority (CMA)
On 3 September 2024, the European Court of Justice (ECJ) ruled that the European Commission (Commission) cannot encourage or accept referrals for below-threshold deals from national competition authorities if those...more
9/6/2024
/ Abuse of Dominance ,
Antitrust Provisions ,
Competition Authorities ,
Court of Justice of the European Union (CJEU) ,
EU ,
European Commission ,
European Merger Control Regulation ,
Jurisdiction ,
Jurisdictional Thresholds ,
Life Sciences ,
Member State ,
Merger Controls ,
Merger Reviews ,
Mergers ,
Technology Sector ,
Threshold Requirements
The European Commission (EC) has launched a formal investigation under its abuse of dominance rules into US life sciences company Zoetis in the area of novel veterinary medicines. The EC alleges that the discontinuation of a...more